132646-47-0

Upstream product

• 401791-02-4 (2-cyclohexyl-5-methyl-oxazol-4-yl)-acetic acid benzyl ester 
• 2719-27-9 cyclohexanylcarbonyl chloride 
• 89724-32-3 2-Cyclohexyl-4-carboxymethyl-5-methyloxazole 
• 401791-01-3 3-(cyclohexanecarbonyl-amino)-4-oxo-pentanoic acid benzyl ester 

Downstream Products

• 132646-48-1 N-(triphenylmethyl)-5-<4-<2-(2-cyclohexyl-5-methyl-4-oxazolyl)ethoxy>benzyl>-2,4-oxazolidinedione 
• 103788-81-4 2-Cyclohexyl-5-methyl-4-[2-(4-nitro-phenoxy)-ethyl]-oxazole 
• 141399-44-2 4-[2-(2-Cyclohexyl-5-methyl-oxazol-4-yl)-ethoxy]-phenylamine 
• 103789-01-1 5-{4-[2-(2-Cyclohexyl-5-methyl-oxazol-4-yl)-ethoxy]-benzyl}-2-imino-thiazolidin-4-one 
• 103788-22-3 C₂₂H₂₅N₂O₄S^(1-)*Na⁽¹⁺⁾ 
• 401791-03-5 toluene-4-sulfonic acid 2-(2-cyclohexyk-5-methyloxazol-4-yl)ethyl ester 
• 1026797-67-0 N-{4-[2-(2-cyclohexyl-5-methyl-oxazol-4-yl)-ethoxy]-benzyl}-hydroxylamine 
• 421558-30-7 4-[2-(2-cyclohexyl-5-methyl-4-oxazolyl)ethoxy]benzaldehyde 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS

The present invention relates to compounds of formula (I) wherein R1 to R8 and n are as defined in the description and claims, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of diseases such as diabetes.

NOVEL HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF

The novel heterocyclic compound of the present invention is a novel heterocyclic compound having the formula (I)R15―C(R14)=N-O― wherein R1 is H or C1-6 alkyl, R2 is H, -CO-C(R4)=C(R4)-R5 wherein R4 is H or C1-4 alkyl, and R5 is C4-8 alkyl, C2-8 alkenyl and the like, and the like, Y is the following group wherein X is O or S, R7 is the same as R4, R8 is R10-C(R9)=C(R9)- wherein R9 is the same as R4, R10 is C3-6 alkyl and the like, and the like, R14 is the same as R4, and R15 is aryl and the like, Y-(CH2)n-O- is bonded to the 6- or 7-position of the tetrahydroisoquinoline skeleton, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof. The compound (I) of the present invention is useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complications, a glucose tolerance improver, an anti-arteriosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated diseases or an agent for the prophylaxis or treatment of syndrome X.

Application of the Dakin-West reaction for the synthesis of oxazole-containing dual PPARα/γ agonists

An improved method for the preparation of a series of oxazole-containing dual PPARα/γ agonists is described. A synthetic sequence utilizing a Dakin-West reaction was devised that allows for the introduction of the oxazole ring either late in the synthetic sequence via aminomalonate-derived chemistry or in pivotal SAR intermediates derived from aspartic acid.